Literature DB >> 21718227

Osteopontin: a potentially important therapeutic target in cancer.

Mansoor Ahmed1, Reeti Behera, Goutam Chakraborty, Shalini Jain, Vinit Kumar, Priyanka Sharma, Anuradha Bulbule, Smita Kale, Santosh Kumar, Rosalin Mishra, Remya Raja, Supriya Saraswati, Rajinder Kaur, Gowrishankar Soundararajan, Dhiraj Kumar, Dhanashri Thorat, Megha Sanyal, Anuja Ramdasi, Pompom Ghosh, Gopal C Kundu.   

Abstract

INTRODUCTION: Cancer is an extremely complex disease and most cancer treatments are limited to chemotherapy, radiation and surgery. The progression of tumours towards malignancy requires the interaction of various cytokines, growth factors, transcription factors and effector molecules. Osteopontin is a cytokine-like, calcium-binding, extracelular-matrix- associated member of the small integrin-binding ligand, N-linked glycoprotein (SIBLING) family of proteins. It plays an important role in determining the oncogenic potential of various cancers. The role of osteopontin in various pathophysiological conditions suggests that the alteration in post-translational modification result in different functional forms that might change its normal physiological functions. AREAS COVERED: Osteopontin -based anticancer therapy, which may provide a new insight for the effective management of cancer. EXPERT OPINION: A better understanding of the signalling mechanism by which osteopontin promotes tumourigenesis may be useful in crafting novel osteopontin -based anticancer therapy. The role of osteopontin in promoting cancer progression is the subject of in depth investigation and thus targeting osteopontin might be a suitable therapeutic approach for the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21718227     DOI: 10.1517/14728222.2011.594438

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  35 in total

Review 1.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

Review 2.  The Rho GTPase signalling pathway in urothelial carcinoma.

Authors:  Solomon L Woldu; Ryan C Hutchinson; Laura-Maria Krabbe; Oner Sanli; Vitaly Margulis
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

3.  An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression.

Authors:  Mansoor Ahmed; Joseph L Sottnik; Garrett M Dancik; Divya Sahu; Donna E Hansel; Dan Theodorescu; Martin A Schwartz
Journal:  Cancer Cell       Date:  2016-09-01       Impact factor: 31.743

4.  SPP1 facilitates cell migration and invasion by targeting COL11A1 in lung adenocarcinoma.

Authors:  Xuan Yi; Linlin Luo; Yanzhen Zhu; Hong Deng; Huitian Liao; Yang Shen; Yan Zheng
Journal:  Cancer Cell Int       Date:  2022-10-20       Impact factor: 6.429

5.  The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas.

Authors:  Ozgur Mete; Caroline Hayhurst; Hussein Alahmadi; Eric Monsalves; Hasan Gucer; Fred Gentili; Shereen Ezzat; Sylvia L Asa; Gelareh Zadeh
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

6.  Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.

Authors:  Katherine E Poruk; Matthew A Firpo; Courtney L Scaife; Douglas G Adler; Lyska L Emerson; Kenneth M Boucher; Sean J Mulvihill
Journal:  Pancreas       Date:  2013-03       Impact factor: 3.327

7.  Evaluation of osteopontin as a potential biomarker for central nervous system embryonal tumors.

Authors:  Yi-Peng Han; Chen-Kai Ma; Shen-Qi Wang; Atsushi Enomoto; Yang Zhao; Masahide Takahashi; Jie Ma
Journal:  J Neurooncol       Date:  2014-05-31       Impact factor: 4.130

Review 8.  Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.

Authors:  Marta Szajnik; Małgorzata Czystowska-Kuźmicz; Esther Elishaev; Theresa L Whiteside
Journal:  Expert Rev Mol Diagn       Date:  2016-06-23       Impact factor: 5.225

9.  Prognostic significance of osteopontin in patients with non-small cell lung cancer: results from a meta-analysis.

Authors:  Yang Liu; Xiaobin Gu; Qunying Lin; Tian Tian; Lijuan Shao; Chao Yuan; Bo Zhang; Kexing Fan
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 10.  Diagnostic value of osteopontin in ovarian cancer: a meta-analysis and systematic review.

Authors:  Zhi-De Hu; Ting-Ting Wei; Min Yang; Ning Ma; Qing-Qin Tang; Bao-Dong Qin; Hai-Tao Fu; Ren-Qian Zhong
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.